| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activation of TLR4 signaling inhibits progression of osteosarcoma by stimulating CD8-positive cytotoxic lymphocytes
|
Yahiro, Kenichiro
|
|
|
69 |
5 |
p. 745-758
|
artikel
|
| 2 |
Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients
|
Kasanen, Henna
|
|
|
69 |
5 |
p. 717-730
|
artikel
|
| 3 |
Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density
|
Nukui, Akinori
|
|
|
69 |
5 |
p. 689-702
|
artikel
|
| 4 |
CD160 expression on CD8+ T cells is associated with active effector responses but limited activation potential in pancreatic cancer
|
Liu, Songyang
|
|
|
69 |
5 |
p. 789-797
|
artikel
|
| 5 |
CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma
|
Pan, Qiu-Zhong
|
|
|
69 |
5 |
p. 825-834
|
artikel
|
| 6 |
Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers
|
Tsang, Julia Y.
|
|
|
69 |
5 |
p. 799-811
|
artikel
|
| 7 |
Current progress in NK cell biology and NK cell-based cancer immunotherapy
|
Tarazona, Raquel
|
|
|
69 |
5 |
p. 879-899
|
artikel
|
| 8 |
Human inflammatory dendritic cells in malignant pleural effusions induce Th1 cell differentiation
|
Gu, Fei-fei
|
|
|
69 |
5 |
p. 779-788
|
artikel
|
| 9 |
Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia
|
Risnik, Denise
|
|
|
69 |
5 |
p. 813-824
|
artikel
|
| 10 |
LincRNA-p21 knockdown reversed tumor-associated macrophages function by promoting MDM2 to antagonize* p53 activation and alleviate breast cancer development
|
Zhou, Lining
|
|
|
69 |
5 |
p. 835-846
|
artikel
|
| 11 |
Long-term surviving cancer patients as a source of therapeutic TCR
|
Inderberg, Else Marit
|
|
|
69 |
5 |
p. 859-865
|
artikel
|
| 12 |
Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial
|
Noguchi, Masanori
|
|
|
69 |
5 |
p. 847-857
|
artikel
|
| 13 |
New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia
|
Jordaens, Stephanie
|
|
|
69 |
5 |
p. 867-877
|
artikel
|
| 14 |
Nonlinear response to cancer nanotherapy due to macrophage interactions revealed by mathematical modeling and evaluated in a murine model via CRISPR-modulated macrophage polarization
|
Leonard, Fransisca
|
|
|
69 |
5 |
p. 731-744
|
artikel
|
| 15 |
Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
|
Kerepesi, Csaba
|
|
|
69 |
5 |
p. 683-687
|
artikel
|
| 16 |
Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients
|
Fröhlich, Anne
|
|
|
69 |
5 |
p. 759-769
|
artikel
|
| 17 |
The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients
|
Rosenbaum, Pierre
|
|
|
69 |
5 |
p. 703-716
|
artikel
|
| 18 |
“Tumor immunology meets oncology (TIMO) XV”, April 25th–27th 2019, Halle/Saale, Germany
|
Steven, André
|
|
|
69 |
5 |
p. 901-909
|
artikel
|
| 19 |
Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients
|
Hurkmans, Daan P.
|
|
|
69 |
5 |
p. 771-777
|
artikel
|
Tijdschrift beschrijving